<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of symptomatic osteoporotic spinal compression fractures.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Academy of Orthopaedic Surgeons (AAOS). American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of symptomatic osteoporotic spinal compression fractures. Rosemont (IL): American Academy of Orthopaedic Surgeons (AAOS); 2010 Sep 24. 177 p. [76 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Fracture, cause unspecified  (E887); Osteoporosis, unspecified  (733.00); Pathologic fracture of vertebrae  (733.13); Pathologic fracture, unspecified site  (733.10); Pathologic fracture, unspecified site  (V13.51)"/><FieldValue Value="MSH: Analgesics ; Analgesics, Opioid ; Bone Density Conservation Agents ; Braces ; Calcitonin ; Complementary Therapies ; Diphosphonates ; Electric Stimulation Therapy ; Exercise ; Fractures, Bone ; Fractures, Compression ; Fractures, Spontaneous ; Kyphoplasty ; Nerve Block ; Organometallic Compounds ; Orthopedic Procedures ; Orthotic Devices ; Osteoporosis ; Osteoporotic Fractures ; Pain Management ; Rest ; Spinal Fractures ; Thiophenes ; Vertebroplasty "/><FieldValue Value="MTH: Analgesics ; Analgesics, Opioid ; Braces-Orthopedic appliances ; Calcitonin ; Complementary therapies ; Diphosphonates ; Electric Stimulation Therapy ; Exercise ; Fracture ; Ibandronate ; Orthotic Devices ; Osteoporosis ; Pain management ; Pathological fracture ; Rest ; Spinal Fractures "/><FieldValue Value="PDQ: calcitonin ; ibandronate ; kyphoplasty ; osteoporosis ; pain therapy ; vertebroplasty "/><FieldValue Value="SNOMEDCT_US: Analgesic  (373265006); Analgesic  (53009005); Back braces  (56144002); Brace  (360316004); Calcitonin  (63730009); Complementary therapy  (225423004); Compression fracture  (21947006); Compression fracture  (443395009); Diphosphonate  (372907000); Diphosphonate  (96281001); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fracture  (125605004); Fracture  (72704001); Fracture of vertebral column  (50448004); Ibandronate  (96287002); Nerve block  (56333001); Nerve block  (64874008); Organic metallic compound  (11621003); Orthotic device  (224898003); Osteoporosis  (64859006); Osteoporotic fracture  (46675001); Osteoporotic vertebral collapse  (240198002); Pain management  (278414003); Pathological fracture  (22640007); Pathological fracture  (268029009); Pathological fracture of vertebra  (274146004); Rest  (258157001); Strontium ranelate  (432727001); Strontium ranelate  (441487000); Therapeutic electrical stimulation  (169430000); Therapeutic electrical stimulation  (57942008); Vertebroplasty  (401226007)"/><FieldValue Value="UMD: Orthoses  (12-837)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Symptomatic osteoporotic spinal compression fractures&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Orthopedic Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Health Plans" /><FieldValue Value="Managed Care Organizations" /><FieldValue Value="Physicians" /><FieldValue Value="Public Health Departments" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To help improve treatment of symptomatic osteoporotic spinal compression fractures in adults based on the current best evidence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To guide qualified physicians through a series of treatment decisions in an effort to improve the quality and efficiency of care &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults (defined as patients 18 years of age and older) with symptomatic osteoporotic spinal compression fractures&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Calcitonin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ibandronate and strontium ranelate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kyphoplasty &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;L2 nerve root block &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following were considered, but a recommendation could not be made for or against the interventions: bed rest, complementary and alternative medicine, opioids/analgesics, treatment with a brace, supervised or unsupervised exercise program, electrical stimulation, improvement of kyphosis angle, and any specific treatment for patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are not neurologically intact.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following were considered but were recommended against: vertebroplasty.&lt;/p&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pain relief &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recovery of mobility and function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fracture rates &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Minimal clinically important improvement &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Study Selection Criteria&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The work group developed &lt;em&gt;a priori&lt;/em&gt; article inclusion criteria for our review. These criteria are the &quot;rules of evidence&quot; and articles that do not meet them are, for the purposes of this guideline, not evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To be included in the systematic reviews (and hence, in this guideline) an article had to be a report of a study that:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Investigates osteoporotic spinal compression fracture patients &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is a full article report of a clinical study (i.e., retrospective case series, medical records review, meeting abstracts, historical articles, editorials, letters, and commentaries are excluded) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Was published in English &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Was published in or after 1966 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appeared in a peer-reviewed publication &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enrolled 10 or more patients per group &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Presented results quantitatively &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Enrolled patients 18 years of age or older (100% of study population) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Is not an in vitro, biomechanical, or cadaver study &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Excluded the following patients (unless results were reported separately): &lt;br /&gt;&#xD;&#xA;    Osteogenesis imperfecta (OI) &lt;br /&gt;&#xD;&#xA;    Solid metastatic tumors of the spine &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For any given follow-up time point in any included study, there must be &amp;ge;50% patient follow-up (if the follow-up is &amp;gt;50% but &amp;lt;80%, the study quality will be downgraded by one level) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Results reported as &quot;post-hoc subgroup analyses&quot; will be excluded &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;When a study's &quot;duration of symptoms&quot; is not the same as those examined by the work group (i.e., 0-2 weeks, 2-6 weeks, etc.) the study will be assigned to the appropriate &quot;duration of symptoms&quot; group based upon the mean duration of symptoms. If a range rather than mean is provided, the higher end of the range will dictate which &quot;duration of symptoms&quot; group the study will be assigned to. For example, a study reporting patient symptoms of 0-4 weeks would be included in the time frame &quot;2-6 weeks&quot; created by the work group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When considering studies for inclusion, the work group included only the best available evidence. Accordingly, they first included Level I evidence. In the absence of two or more studies of this Level, they sequentially searched for and included Level II through Level IV evidence, and did not proceed to a lower level if there were two or more studies of a higher level. For example, if there were two Level II studies that addressed a recommendation, they did not include Level III or IV studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Literature Searches&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The work group attempted to make the searches for articles comprehensive. Using comprehensive literature searches ensures that the evidence they considered for this guideline is not biased for (or against) any particular point of view.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The work group searched for articles published from January 1966 to December 31, 2009. They searched four electronic databases: PubMed, EMBASE, CINAHL, and The Cochrane Central Register of Controlled Trials. Strategies for searching electronic databases were constructed by a medical librarian using previously published search strategies to identify relevant studies.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;They supplemented searches of electronic databases with manual screening of the bibliographies of all retrieved publications. They also searched the bibliographies of recent systematic reviews and other review articles for potentially relevant citations. Finally, work group members provided a list of potentially relevant studies that were not identified by the searches. All articles identified were subject to the study selection criteria listed above.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The study attrition diagram in Appendix III in the original guideline document provides details about the inclusion and exclusion of the studies considered for this guideline. The search strategies used to identify these studies are provided in Appendix IV in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;50 articles were included.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence for Primary Research Question&lt;sup&gt;1&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Levels of Evidence for Primary Research Question&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;5&quot;&gt;Types of Studies&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td style=&quot;width: 5%;&quot; valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Therapeutic Studies&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            Investigating the results of treatment&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Prognostic Studies&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            Investigating the effects of a patient characteristic on the outcome of disease&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Diagnostic Studies&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            Investigating a diagnostic test&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;Economic and Decision Analyses&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;            Developing an economic or decision model&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level I&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality randomized trial with statistically significant difference or no statistically significant difference but narrow confidence intervals &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level I randomized controlled trials (RCTs) (and study results were homogenous&lt;sup&gt;3&lt;/sup&gt;) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;High quality prospective study&lt;sup&gt;4&lt;/sup&gt; (all patients were enrolled at the same point in their disease with &amp;ge;80% follow-up of enrolled patients) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Testing of previously developed diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from many studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level I studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level II&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality RCT (e.g., &amp;lt;80% follow-up, no blinding, or improper randomization) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Prospective&lt;sup&gt;4&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level II studies or Level I studies with inconsistent results &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Retrospective study&lt;sup&gt;6&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Untreated controls from an RCT &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Lesser quality prospective study (e.g., patients enrolled at different points in their disease or &amp;lt;80% follow-up) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level II studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Development of diagnostic criteria on consecutive patients (with universally applied reference &quot;gold&quot; standard) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level II studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sensible costs and alternatives; values obtained from limited studies; with multiway sensitivity analyses &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level II studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level III&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Retrospective&lt;sup&gt;6&lt;/sup&gt; comparative study&lt;sup&gt;5&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case control study&lt;sup&gt;7&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Study of nonconsecutive patients; without consistently applied reference &quot;gold&quot; standard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Analyses based on limited alternatives and costs; and poor estimates &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Systematic review&lt;sup&gt;2&lt;/sup&gt; of Level III studies &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level IV&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series&lt;sup&gt;8&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case series &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Case-control study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Poor reference standard &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Analyses with no sensitivity analyses &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Level V&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Expert opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt; A complete assessment of quality of individual studies requires critical appraisal of all aspects of the study design.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;2&lt;/sup&gt; A combination of results from two or more prior studies.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;3&lt;/sup&gt; Studies provided consistent results.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;4&lt;/sup&gt; Study was started before the first patient enrolled.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;5&lt;/sup&gt; Patients treated one way (e.g., cemented hip arthroplasty) compared with a group of patients treated in another way (e.g., uncemented hip arthroplasty) at the same institution.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;6&lt;/sup&gt; The study was started after the first patient enrolled.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;7&lt;/sup&gt; Patients identified for the study based on their outcome, called &quot;cases&quot;; e.g., failed total hip arthroplasty, are compared to those who did not have outcome, called &quot;controls&quot;; e.g., successful total hip arthroplasty.&lt;br /&gt;&#xD;&#xA;&lt;sup&gt;8&lt;/sup&gt; Patients treated one way with no comparison group of patients treated in another way.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Meta-Analysis of Randomized Controlled Trials" /><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Data Extraction&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Data elements extracted from studies were defined in consultation with the physician work group. The elements extracted are shown in Appendix V in the original guideline document. Evidence tables were constructed to summarize the best evidence pertaining to each preliminary recommendation. Disagreements about the accuracy of extracted data were resolved by consensus and consulting the work group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Judging the Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Determining the quality of the included evidence is vitally important when preparing any evidence-based work product. Doing so conveys the amount of confidence one can have in any study's results. One has more confidence in high quality evidence than in low quality evidence.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assigning a level of evidence on the basis of study design plus other quality characteristics ties the levels of evidence the work group reports more closely to quality than levels of evidence based only on study design. Because the work group ties quality to levels of evidence, they are able to characterize the confidence one can have in their results. Accordingly, they characterize the confidence one can have in Level I evidence as high, the confidence one can have in Level II and III evidence as moderate, and the confidence one can have in Level IV and V evidence as low. Similarly, throughout the guideline they refer to Level I evidence as reliable, Level II and III evidence as moderately reliable, and Level IV and V evidence as not reliable.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Statistical Methods&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When possible the results of statistical analysis conducted by the American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines Unit using STATA 10.0 (StataCorp LP, College Station, Texas) are reported. The program was used to determine the magnitude of the treatment effect. For data reported as means (and associated measures of dispersion) the mean difference between groups was calculated. For proportions, the odds ratio was calculated as a measure of treatment effect. When no events occur (&quot;zero event&quot;) in a proportion, the variance of the arcsine difference was used to determine statistical significance (p &amp;lt; 0.05).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To compare recurrent and adjacent fracture rates the work group reports the proportion of patients that experienced a fracture and percentage of patients that experienced a fracture. The variance of the arcsine difference was used to determine statistical significance (p &amp;lt; 0.05) of fracture rates.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The work group performed meta-analyses using the random effects method of DerSimonian and Laird. Heterogeneity was assessed with the I-squared statistic. All meta-analyses were performed using STATA 10.0 (StataCorp LP, College Station, Texas) and the &quot;metan&quot; command.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To assess the power of an outcome to detect a statistically significant difference the work group determined whether the number of patients in the study was sufficient to detect a small, medium, or large effect, while assuming an alpha of 0.05 as the significance level, 80% power, and Cohen's definitions of small, medium, and large effects (a small effect is d = 0.2, a medium effect is d = 0.5, and a large effect is d = 0.8). When a study with a nonsignificant difference that was unable to detect a large effect it was categorized as low power. Studies able to detect medium effects or with statistically significant differences were categorized as high power.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;When published studies report measures of dispersion other than the standard deviation the value was estimated to facilitate calculation of the treatment effect. In studies that report standard errors or confidence intervals the standard deviation was back-calculated. In studies that only report the median, range, and size of the trial, they estimated the means and variances according to a published method. Studies that report results in graphical form were analyzed with TechDig 2.0 (Ronald B. Jones, Mundelein, Illinois) to estimate the mean and variance.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In some circumstances statistical testing was conducted by the authors and measures of dispersion were not reported. In the absence of measures of dispersion, the results of the statistical analyses conducted by the authors are included in the analysis and are identified as those of the study authors.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus (Nominal Group Technique)" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline and systematic review were prepared by the American Academy of Orthopaedic Surgeons (AAOS) Treatment of Symptomatic Osteoporotic Spinal Compression Fractures guideline work group with the assistance of the AAOS Clinical Practice Guidelines Unit in the Department of Research and Scientific Affairs at the AAOS (see Appendix I in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To develop this guideline, the work group held an introductory meeting to develop the scope of the guideline on March 28, 2009. Upon completion of the systematic review, the work group met again on February 27 and 28, 2010 to write and vote on the final recommendations and rationales for each recommendation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Formulating Preliminary Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The work group began work on this guideline by constructing a set of preliminary recommendations. These recommendations specify [what] should be done in [whom], [when], [where], and [how often or how long]. They function as questions for the systematic review, not as final recommendations or conclusions. Preliminary recommendations are almost always modified on the basis of the results of the systematic review. Once established, these &lt;em&gt;a priori&lt;/em&gt; preliminary recommendations cannot be modified until the final work group meeting, they must be addressed by the systematic review, and the relevant review results must be presented in the final guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Defining the Strength of the Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;To develop the strength of a recommendation, AAOS staff first assigned a preliminary strength for each recommendation that took only the quality and quantity of the available evidence into account (see &quot;Rating Scheme for the Strength of the Recommendations&quot; field). Work group members then modified the preliminary strength using the &quot;Form for Assigning Strength of Recommendation (Interventions)&quot; shown in Appendix VII in the original guideline document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consensus Development&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The recommendations and their strength were voted on using a structured voting technique known as the nominal group technique. The work group presents details of this technique in Appendix VIII in the original guideline document. Voting on guideline recommendations was conducted using a secret ballot and work group members were blinded to the responses of other members. If disagreement between work group members was significant, there was further discussion to see whether the disagreement(s) could be resolved. Up to three rounds of voting were held to attempt to resolve disagreements. If disagreements were not resolved following three voting rounds, no recommendation was adopted. Lack of agreement is a reason that the strength for some recommendations is labeled &quot;Inconclusive.&quot;&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Strength of Recommendation &lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Strength of Recommendation&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Overall Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Description of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Good&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Level I evidence from more than one study with consistent findings for recommending for or against the intervention or diagnostic.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Level II or III evidence from more than one study with consistent findings, or Level I evidence from a single study for recommending for or against the intervention or diagnostic.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Poor&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Level IV or V evidence from more than one study with consistent findings, or Level II or III evidence from a single study for recommending for against the intervention or diagnostic.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Inconclusive&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None or conflicting&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The evidence is insufficient or conflicting and does not allow a recommendation for or against the intervention or diagnostic.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No evidence&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is no supporting evidence. In the absence of reliable evidence, the work group is making a recommendation based on their clinical opinion considering the known harms and benefits associated with the treatment.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;American Academy of Orthopaedic Surgeons Guideline Language&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: American Academy of Orthopaedic Surgeons Guideline Language&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Guideline Language&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Strength of Recommendation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The work group &lt;strong&gt;&lt;em&gt;recommends&lt;/em&gt;&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The work group &lt;strong&gt;&lt;em&gt;suggests&lt;/em&gt;&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;&lt;em&gt;Option&lt;/em&gt;&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The work group is &lt;strong&gt;&lt;em&gt;unable to recommend for or against&lt;/em&gt;&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Inconclusive&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;In the absence of reliable evidence, it is the &lt;strong&gt;&lt;em&gt;opinion&lt;/em&gt;&lt;/strong&gt; of this work group&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Peer Review&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The draft of the guideline and evidence report was peer reviewed by an external, outside specialty panel that was nominated &lt;em&gt;a priori&lt;/em&gt; by the physician work group prior to the development of the guideline. The physician members of the American Academy of Orthopaedic Surgeons (AAOS) Guidelines and Technology Oversight Committee and the Evidence Based Practice Committee also provided peer review of the draft document. Peer review was accomplished using a structured peer review form (see Appendix IX in the original guideline document). The draft guideline was sent to a total of 32 reviewers and 11 returned reviews (see Appendix X in the original guideline document). The disposition of all non-editorial peer review comments was documented and accompanied this guideline through the public commentary and the AAOS guideline approval process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Public Commentary&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After modifying the draft in response to peer review, the guideline was subjected to a thirty day period of &quot;Public Commentary.&quot; Commentators consist of members of the AAOS Board of Directors (BOD), members of the Council on Research, Quality Assessment, and Technology (CORQAT), members of the Board of Councilors (BOC), and members of the Board of Specialty Societies (BOS). Based on these bodies, over 200 commentators had the opportunity to provide input into this guideline development process. Of these, forty-nine members received the document for review and one member returned public comments (see Appendix X in the original guideline document).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;The AAOS Guideline Approval Process&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Following public commentary, the draft was again modified by the AAOS Clinical Practice Guidelines Unit and work group members. This final guideline draft was approved by the AAOS Guidelines Oversight Committee, the AAOS Evidence Based Practice Committee, the AAOS Council on Research, Quality Assessment, and Technology, and the AAOS Board of Directors. Descriptions of these bodies are provided in Appendix II in the original guideline document.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Definitions of the strength of recommendations (&lt;strong&gt;Strong, Moderate, Weak, Inconclusive, &lt;/strong&gt;and&lt;strong&gt; Consensus&lt;/strong&gt;) are provided at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Note from the American Academy of Orthopaedic Surgeons (AAOS)&lt;/strong&gt;: This summary does not contain rationales that explain how and why these recommendations were developed nor does it contain the evidence supporting these recommendations. All readers of this summary are strongly urged to consult the full guideline and evidence report (see &quot;Guideline Availability&quot; and &quot;Availability of Companion Documents&quot; fields) for this information. The work group is confident that those who read the full guideline and evidence report will see that the recommendations were developed using systematic evidence-based processes designed to combat bias, enhance transparency, and promote reproducibility.&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The work group suggests that patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms suggesting an acute injury (0-5 days after identifiable event or onset of symptoms) and who are neurologically intact be treated with calcitonin for 4 weeks.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Moderate&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ibandronate and strontium ranelate are options to prevent additional symptomatic fractures in patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Weak&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group is unable to recommend for or against bed rest, complementary and alternative medicine, or opioids/analgesics for patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are neurologically intact.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Inconclusive&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is an option to treat patients who present with an osteoporotic spinal compression fracture at L3 or L4 on imaging with correlating clinical signs and symptoms suggesting an acute injury and who are neurologically intact with an L2 nerve root block.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Weak&lt;/strong&gt; &lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group is unable to recommend for or against treatment with a brace for patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are neurologically intact.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Inconclusive&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group is unable to recommend for or against a supervised or unsupervised exercise program for patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are neurologically intact.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Inconclusive&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group is unable to recommend for or against electrical stimulation for patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are neurologically intact.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Inconclusive&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group recommends against vertebroplasty for patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are neurologically intact.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Strong&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kyphoplasty is an option for patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are neurologically intact.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Weak&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group is unable to recommend for or against improvement of kyphosis angle in the treatment of patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Inconclusive&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group is unable to recommend for or against any specific treatment for patients who present with an osteoporotic spinal compression fracture on imaging with correlating clinical signs and symptoms and who are not neurologically intact.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Strength of Recommendation: Inconclusive&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence&lt;/strong&gt;: See the &quot;Rating Scheme for the Strength of the Evidence&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Strength of Recommendation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Strength of Recommendation&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Strength&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Overall Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Description of Evidence&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Good&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Level I evidence from more than one study with consistent findings for recommending for or against the intervention or diagnostic.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Fair&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Level II or III evidence from more than one study with consistent findings, or Level I evidence from a single study for recommending for or against the intervention or diagnostic.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Poor&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Level IV or V evidence from more than one study with consistent findings, or Level II or III evidence from a single study for recommending for against the intervention or diagnostic.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Inconclusive&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;None or conflicting&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The evidence is insufficient or conflicting and does not allow a recommendation for or against the intervention or diagnostic.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;No evidence&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;There is no supporting evidence. In the absence of reliable evidence, the work group is making a recommendation based on their clinical opinion considering the known harms and benefits associated with the treatment.&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;American Academy of Orthopaedic Surgeons Guideline Language&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: American Academy of Orthopaedic Surgeons Guideline Language&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Guideline Language&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Strength of Recommendation&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The work group &lt;strong&gt;&lt;em&gt;recommends&lt;/em&gt;&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Strong&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The work group &lt;strong&gt;&lt;em&gt;suggests&lt;/em&gt;&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;&lt;em&gt;Option&lt;/em&gt;&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Weak&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;The work group is &lt;strong&gt;&lt;em&gt;unable to recommend for or against&lt;/em&gt;&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Inconclusive&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;In the absence of reliable evidence, it is the &lt;strong&gt;&lt;em&gt;opinion&lt;/em&gt;&lt;/strong&gt; of this work group&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is specifically stated for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The aim of treatment is pain relief and recovery of mobility.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Most treatments are associated with some known risks, especially invasive and operative treatments. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In one study, calcitonin was associated with mild dizziness and enteric disturbances. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In one study, there were no statistically significant differences in adverse events between ibandronate and placebo groups including those in the upper gastrointestinal tract. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One study investigated daily strontium ranelate for vertebral fractures compared to placebo. The occurrence of adverse events was similar between patients assigned to placebo or strontium ranelate. The only statistically significant differences were diarrhea, which occurred more frequently in patients receiving strontium ranelate, and incidence of gastritis, which occurred more frequently in patients receiving placebo. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Contraindications vary widely based on the treatment administered. Therefore, discussion of available treatments and procedures applicable to the individual patient rely on mutual communication between the patient and physician, weighing the potential risks and benefits for that patient.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;This Clinical Practice Guideline was developed by an American Academy of Orthopaedic Surgeons (AAOS) physician volunteer Work Group based on a systematic review of the current scientific and clinical information and accepted approaches to treatment and/or diagnosis. This Clinical Practice Guideline is not intended to be a fixed protocol, as some patients may require more or less treatment or different means of diagnosis. Clinical patients may not necessarily be the same as those found in a clinical trial. Patient care and treatment should always be based on a clinician's independent medical judgment, given the individual patient's clinical circumstances. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Some drugs or medical devices referenced or described in this Clinical Practice Guideline may not have been cleared by the Food and Drug Administration (FDA) or may have been cleared for a specific use only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The summary of recommendations is not intended to stand alone. Treatment decisions should be made in light of all circumstances presented by the patient. Treatments and procedures applicable to the individual patient rely on mutual communication between patient, physician, and other healthcare practitioners. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;This guideline should not be construed as including all proper methods of care or excluding methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific procedure or treatment must be made in light of all circumstances presented by the patient and the needs and resources particular to the locality or institution. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The primary purpose of the present document is to provide interested readers with full documentation about not only the recommendations, but also about how the work group arrived at those recommendations. This document is also posted on the American Academy of Orthopaedic Surgeons (AAOS) website at &lt;a href=&quot;http://www.aaos.org/research/guidelines/guide.asp&quot; title=&quot;AAOS Web site&quot;&gt;http://www.aaos.org/research/guidelines/guide.asp&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Shorter versions of the guideline are available in other venues. Publication of most guidelines is announced by an Academy press release, articles authored by the work group and published in the &lt;em&gt;Journal of the American Academy of Orthopaedic Surgeons&lt;/em&gt;, and articles published in AAOS &lt;em&gt;Now&lt;/em&gt;. Most guidelines are also distributed at the AAOS Annual Meeting in various venues such as on Academy Row and at Committee Scientific Exhibits.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Selected guidelines are disseminated by webinar, an Online Module for the Orthopaedic Knowledge Online website, Radio Media Tours, Media Briefings, and by distributing them at relevant Continuing Medical Education (CME) courses and at the AAOS Resource Center.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Other dissemination efforts outside of the AAOS will include submitting the guideline to the National Guideline Clearinghouse and distributing the guideline at other medical specialty societies' meetings.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Patient Resources" /><FieldValue Value="Quick Reference Guides/Physician Guides" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;American Academy of Orthopaedic Surgeons (AAOS). American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of symptomatic osteoporotic spinal compression fractures. Rosemont (IL): American Academy of Orthopaedic Surgeons (AAOS); 2010 Sep 24. 177 p. [76 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Sep 24" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Academy of Orthopaedic Surgeons - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American Academy of Orthopaedic Surgeons&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline and systematic review were prepared by the American Academy of Orthopaedic Surgeons (AAOS) Treatment of Symptomatic Osteoporotic Spinal Compression Fractures guideline work group with the assistance of the AAOS Clinical Practice Guidelines Unit in the Department of Research and Scientific Affairs at the AAOS.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Work Group&lt;/em&gt;: Stephen I Esses, MD, &lt;em&gt;Chair&lt;/em&gt;, Southwest Orthopedic Group; Robert McGuire, MD, &lt;em&gt;Vice-Chair&lt;/em&gt;, University of Mississippi Medical Center, Department of Orthopedic Surgery; John Jenkins, MD, University of Mississippi Medical Center, Division of Rheumatology, Department of Medicine; Joel Finkelstein, MD; Eric Woodard, MD, New England Baptist Hospital&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Guidelines and Technology Oversight Chair&lt;/em&gt;: William C. Watters III, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Guidelines and Technology Oversight Vice-Chair&lt;/em&gt;: Michael J. Goldberg, MD, Department of Orthopaedics, Seattle Children's Hospital&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Evidence Based Practice Committee Chair&lt;/em&gt;: Michael Keith, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;American Academy of Orthopaedic Surgeons (AAOS) Staff&lt;/em&gt;: Charles M. Turkelson, PhD, Director of Research and Scientific Affairs; Janet L. Wies, MPH, AAOS Clinical Practice Guideline Manager; Patrick Sluka, MPH, AAOS Research Analyst; Kevin M. Boyer, AAOS Research Analyst; Kristin Hitchcock, MLS, AAOS Medical Librarian&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Special Acknowledgements&lt;/em&gt;: Sara Anderson, MPH; Laura Raymond, MA&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;All members of the American Academy of Orthopaedic Surgeons (AAOS) work group disclosed any conflicts of interest prior to the development of the recommendations for this guideline. Conflicts of interest are disclosed in writing with the American Academy of Orthopaedic Surgeons via a private on-line reporting database and also verbally at the recommendation approval meeting.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Disclosure Items&lt;/strong&gt;: (n) = Respondent answered 'No' to all items indicating no conflicts. 1 = Board member/owner/officer/committee appointments; 2 = Medical/orthopaedic publications; 3 = Royalties; 4 = Speakers bureau/paid presentations; 5A = Paid consultant; 5B = Unpaid consultant; 6 = Research or institutional support from a publisher; 7 = Research or institutional support from a company or supplier; 8 = Stock or stock options; 9 = Other financial/material support from a publisher; 10 = Other financial/material support from a company or supplier.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Stephen I Esses, MD&lt;/strong&gt; (Houston, TX): 2 (Orthopedics; Spine; THE SPINE JOURNAL). Submitted on: 10/23/2009 and last confirmed as accurate on 01/22/2010.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Joel A Finkelstein, MD&lt;/strong&gt; (Toronto, ON, Canada): 7 (Stryker; Synthes). Submitted on: 02/03/2009.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;John Jenkins&lt;/strong&gt; (Jackson, MS): 4 (Norvartis; Procter &amp;amp; Gamble; Roche). Submitted on: 03/11/2009.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Robert A McGuire, Jr MD&lt;/strong&gt; (Jackson, MS): 1 (AOSpine North America chairman); 2 (Journal of Spinal Disorders); 3 (DePuy, A Johnson &amp;amp; Johnson Company); 5A (Synthes); 7 (AO; Stryker). Submitted on: 02/16/2009.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Eric John Woodard, MD&lt;/strong&gt; (Boston, MA): 1 (AOSpine); 4 (DePuy, A Johnson &amp;amp; Johnson Company; Stryker; Synthes); 5A (invivo therapeutics); 7 (Synthes; AOSpine); 8 (Medtronic); 10 (Nanoventures). Submitted on: 03/24/2009.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;William Charles Watters III, MD&lt;/strong&gt; (Houston, TX): 1 (North American Spine Society; American Board of Spine Surgery; Board of Adviser Official Disability Guidelines; Associate Member of The Editorial Board, The Spine Journal; Med Center Ambulatory Surgery Center); 2 (The Spine Journal); 4 (Stryker; Synthes); 5A (Orthofix, Inc.; Stryker); 8 (Intrinsic Therapeutics). Submitted on: 08/14/2009.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.aaos.org/research/guidelines/SCFguideline.asp&quot; title=&quot;AAOS Web site&quot;&gt;American Academy of Orthopaedic Surgeons Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American Academy of Orthopaedic Surgeons, 6300 North River Road, Rosemont, IL 60018-4262. Telephone: (800) 626-6726 (800 346-AAOS); Fax: (847) 823-8125; Web site: &lt;a href=&quot;http://www.aaos.org/&quot; title=&quot;AAOS Web site&quot;&gt;www.aaos.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;American Academy of Orthopaedic Surgeons (AAOS) Guideline on the treatment of osteoporotic spinal compression fractures. Summary of recommendations. Rosemont (IL): American Academy of Orthopaedic Surgeons; 2010 Sep. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.aaos.org/research/guidelines/SCFsummary.pdf&quot; title=&quot;AAOS Web site&quot;&gt;American Academy of Orthopaedic Surgeons (AAOS) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from the American Academy of Orthopaedic Surgeons, 6300 North River Road, Rosemont, IL 60018-4262. Telephone: (800) 626-6726 (800 346-AAOS); Fax: (847) 823-8125; Web site: &lt;a href=&quot;http://www.aaos.org&quot; title=&quot;AAOS Web site&quot;&gt;www.aaos.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Osteoporosis and spinal fractures. Rosemont (IL): American Academy of Orthopaedic Surgeons; 2010 May. Available from the &lt;a href=&quot;http://orthoinfo.aaos.org/topic.cfm?topic=A00538&quot; title=&quot;AAOS Web site&quot;&gt;American Academy of Orthopaedic Surgeons Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on April 21, 2011.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. For more information, please contact AAOS Department of Research and Scientific Affairs, 6300 North River Road, Rosemont, IL 60018; Phone: (847) 823-7186; Fax: (847) 823-8125.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
